Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity
Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, Wioletta Skronska-Wasek, Rebecca Langlois, Nicolas Sabarth, Renate Konopitzky, Fidel Ramirez, Katharina Lehr, Tobias Mayr, David Kind, Coralie Viollet, Lee Kim Swee, Jutta Petschenka, Karim C. El Kasmi, Elfriede Noessner, Kerstin Kitt, Stefan Pflanz
Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, Wioletta Skronska-Wasek, Rebecca Langlois, Nicolas Sabarth, Renate Konopitzky, Fidel Ramirez, Katharina Lehr, Tobias Mayr, David Kind, Coralie Viollet, Lee Kim Swee, Jutta Petschenka, Karim C. El Kasmi, Elfriede Noessner, Kerstin Kitt, Stefan Pflanz
View: Text | PDF
Research Article Immunology Oncology

CD206+ tumor-associated macrophages cross-present tumor antigen and drive antitumor immunity

  • Text
  • PDF
Abstract

In many solid cancers, tumor-associated macrophages (TAM) represent the predominant myeloid cell population. Antigen (Ag) cross-presentation leading to tumor Ag–directed cytotoxic CD8+ T cell responses is crucial for antitumor immunity. However, the role of recruited monocyte-derived macrophages, including TAM, as potential cross-presenting cells is not well understood. Here, we show that primary human as well as mouse CD206+ macrophages are effective in functional cross-presentation of soluble self-Ag and non–self-Ag, including tumor-associated Ag (TAA), as well as viral Ag. To confirm the presence of cross-presenting TAM in vivo, we performed phenotypic and functional analysis of TAM from B16-F10 and CT26 syngeneic tumor models and have identified CD11b+F4/80hiCD206+ TAM to effectively cross-present TAA. We show that CD11b+CD206+ TAM represent the dominant tumor-infiltrating myeloid cell population, expressing a unique cell surface repertoire, promoting Ag cross-presentation and Ag-specific CD8+ T cell activation comparable with cross-presenting CLEC9A+ DCs (cDC1). The presence of cross-presenting CD206+ TAM is associated with reduced tumor burden in mouse syngeneic tumor models and with improved overall survival in cutaneous melanoma patients. Therefore, the demonstration of effective Ag cross-presentation capabilities of CD206+ TAM, including their clinical relevance, expands our understanding of TAM phenotypic diversity and functional versatility.

Authors

Madhura Modak, Ann-Kathrin Mattes, Daniela Reiss, Wioletta Skronska-Wasek, Rebecca Langlois, Nicolas Sabarth, Renate Konopitzky, Fidel Ramirez, Katharina Lehr, Tobias Mayr, David Kind, Coralie Viollet, Lee Kim Swee, Jutta Petschenka, Karim C. El Kasmi, Elfriede Noessner, Kerstin Kitt, Stefan Pflanz

×

Figure 4

CD206+ macrophages are efficient in cross-presenting soluble TAA.

Options: View larger image (or click on image) Download as PowerPoint
CD206+ macrophages are efficient in cross-presenting soluble TAA.
(A) De...
(A) Detection of TyrD369–377/MHC I complex with D7 TCRL antibody on indicated MDM subsets. MDM subsets were pretreated with TyrD short peptide (red histogram) or Scr short peptide (gray histograms). (B) Bar diagram represents percentage of positive cells as detected by reactivity profile of D7 antibody upon treatment of MDM subsets with Scr short peptide (open bars) and TyrD short peptide (filled bars). (C) As in A, but MDM were treated with TyrD long peptide (red histogram) or with Scr long peptide (gray histogram). (A and C) Data are representative from 5 different donors. (D) As in B, but MDM were treated with Scr long peptide (open bars) or TyrD long peptide (filled bars). (B and D) Data show mean ± SEM (n = 4–5 donors). (E and F) Bar diagram represents IFN-γ levels in the T58/MDM coculture supernatant where MDM subsets were pretreated with Scr short peptide (open bars) or TyrD short peptide (filled bars) (E), and where MDM were pretreated with Scr long peptide (open bars) or TyrD long peptide (filled bars) (F). Data show mean ± SEM (n = 3–4 donors). (G) Bar diagram represents IFN-γ levels in the T58/MDM coculture supernatants as analyzed by IFN-γ CBA assay, wherein MDM were unexposed (open bars) or were first exposed to UV-treated apoptotic COLO829 cells for 5 hours (filled bars). Data show mean ± SEM (n = 4 donors). (B and D–F) Unpaired Student’s t test followed by Holm-Šídák test for multiple comparisons was performed. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts